AMC

AMC

There have been more than 30 initial public offerings of biotechnology companies so far this year, Timothy Hay reports in a Wall Street Journal blog article this morning (Hat tip I.V. for forwarding).

While some have referred to this as an “IPO window,” indicating that it could just as easily slam shut again, investors at the Bio Investor Forum characterized the phenomenon differently.

“There is no reason to believe this window is going to shut any time soon,” said Evan McColloch, a portfolio manager with Franklin Templeton Investments. “As far as I can tell, this will continue for a while.”

Read: Biotechnology Boom is Here to Stay, Investors Say